https://www.thebodypro.com/article/first-trials-of-hiv-vaccine-using-broadly-neutrali
HIV Prevention MethodsConference Coverage

First Trials of HIV Vaccine Using Broadly Neutralizing Antibodies Begin

Antibodies
Svisio for iStock via Thinkstock
    VRC01 was shown to be highly effective in animal studies, disabling a variety of HIV strains across all major subtypes of the virus, including during both acute and chronic infection.
    Share
    The main goals of these clinical trials are to establish that it is at least 50% effective in preventing HIV infection and to determine the plasma levels of antibodies that are necessary to confer that protection.
    Share
    Barbara Jungwirth

    Barbara Jungwirth

    @bjungwirthNY

    Barbara Jungwirth is an experienced freelance journalist, writer, and translator who has been reporting on HIV for TheBody and TheBodyPro since 2002.